Low-Dose Cariprazine for MDD Tied to Anxiety Reduction
NEW ORLEANS — Low-dose cariprazine (Vraylar) was associated with reductions in anxiety for patients with major depressive disorder (MDD), and the potential adjunctive therapy for this population also demonstrated improvements across most individual symptoms of depression, according to two post hoc analyses of a phase III trial. When combined with an antidepressant for MDD patients […]
Add-On Vraylar Tied to Easing of Recurrent Depressive Symptoms
NEW ORLEANS — Adjunctive cariprazine (Vraylar) was linked with a reduction in depressive symptoms for patients with major depressive disorder (MDD), who had an inadequate response to current therapy, according to a phase III study. When added to a first-line antidepressant, 1.5 mg of once-daily cariprazine resulted in significantly greater average reductions in Montgomery-Åsberg Depression […]